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within 30 days of the prescription’s origination date. RESULTS: Using the PQA-
developed PMN measure, these 100 pharmacies had an overall PMN rate of 9.3%. 
The measure could be calculated using the pharmacy transaction data; however, 
some adjustments (e.g., assumption that patient did not receive drug at another 
pharmacy) had to be made. CONCLUSIONS: Retail pharmacy data can be used to 
measure quality indicators, like PMN. These measures will have limitations, as 
do other quality indicator measures.  
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OBJECTIVES: We present the methodology for a near-real-time 
Pharmacovigilance & Drug Safety System (PDSS) to detect relationships between 
indications, drugs and outcomes. Combinations are user-selectable from a 
library of clinical scenarios including indications, agents and outcomes. 
Exemplary results for drug-outcome pairs from the PDSS are illustrated. 
METHODS: Deidentified claims data for five million individuals covering a 12-
month span was analyzed. A ‘Heat-Map’ was generated with relative risk (RR) for 
combinations of 73 DDCs and 39 HOIs. Clinical indications (on- and off-label), 
presence of drug, and outcomes were identified as, respectively,1+ ICD-9 
claim(s), 1+ NDC codes for a drug refill, and outcome code present in months 6-
12 but not in month 1-6. RR and Chi-Squared were calculated for every 
combination (SAS 9.3). RESULTS: PDSS generated 47,319 indication-drug-
outcome combinations. Run time was less than 48 hours. At a nominal threshold 
of at least 5 unique patients chi-square (X2) value of over 5, 13,094 (28%) of the 
combinations were identified for further inspection. Example results included: 
GERD-PPI-Bleeding:0.648 (x2=139); GERD-PPI-Fracture:1.42(x2=11.1); Hypertension-
ACEI-CHF:0.81(x2=19.5); Hypertension-metoprolol-Renal failure:1.78(x2=86.7); 
Non-valvular Atrial fibrillation-Dabigatran-Bleeding:1.1(x2=0.2); Valvular Atrial 
fibrillation-Dabigatran-Bleeding:1.3 (x2=2.6); mechanical heart valve-dabigatran-
stroke:8.76(x2=6.5). CONCLUSIONS: The PDSS rapidly quantifies indication-drug-
outcome combinations from real-world data. Such a system can provide 
prospective and continuous drug surveillance and comparative effectiveness & 
harms analysis. This can permit more efficient targeting of further analyses. 
Finally, the PDSS is constructed such that it is rapidly able to incorporate new 
indication, drug, and/or outcome data from claims or clinical (i.e. EMR) data sets.  
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OBJECTIVES: To examine the concordance in diabetes diagnosis between 
electronic medical records (EMR) and claims data and to explore an appropriate 
definition for diabetes in EMR data. METHODS: Retrospective study using the 
Linked Quintile EMR and MarketScan Commercial and Medicare Databases 
(MSN). Patients with at least one EMR every year and continuous enrollment in 
MSN between January 1, 2009 through December 31, 2011 were included in the 
study. Patients with at least one inpatient or two outpatient claims for diabetes 
(ICD-9-CM 250.xx) in MSN were identified as diabetic patients. Diabetes was 
defined in the EMR data using various criteria, including HbA1C≥6.5%, diabetes in 
the problem list, any insulin prescription, ≥2 oral anti-diabetic agents, and ≥2 
abnormal fasting plasma glucose tests. An extended definition of diabetes based 
on the presence of any of the criteria mentioned above was also evaluated. 
RESULTS: Among the 257,899 patients meeting the study inclusion criteria, 
34,383 were identified as diabetic patients using MSN claims. When the extended 
definition was used, 27,219 patients were defined as diabetic in EMR, an 11.8% 
increase compared with those identified using the HbA1C≥6.5% criterion, and 
2.35 times of those with a diabetes diagnosis in the problem list. Assuming 
claims to be the gold standard, the extended definition also had a higher 
sensitivity at 79.2% (versus 70.8% when HbA1c≥6.5% criterion was used alone 
and 33.6% when the criterion of diabetes on problem list was used alone). The 
specificity of the extended definition was 97.9%. CONCLUSIONS: This study 
explored the feasibility of identifying the diabetic patients in the Quintile EMR 
data and confirmed good concordance of the diabetes definition between EMRs 
and claims. When linked EMR and claims data are used, the diagnosis of diabetes 
is strengthened when patients have evidence of diabetes in both EMR and 
claims.  
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OBJECTIVES: Mapping the pharmaceutical distribution margin variations 
according to country wealth and therapy areas may provide insight into the 
developing trends of medicine supply across the globe. To confirm any trends, 
we compared pharmaceutical margins for diabetic, multiple sclerosis and 
oncology drugs in various countries to the country gross domestic product (GDP). 
METHODS: Using data from PRICENTRICTM, we collected ex-factory and public 
prices (excl. VAT) for various branded products from three therapy areas 
(diabetes, multiple sclerosis and oncology). Countries with unregulated 
distribution margins were excluded from the analysis. We calculated the average 
distribution margins between ex-factory price and public price across countries, 
regions and therapy areas. We also compared distribution margins to GDP per 
capita (International Monetary Fund 2012) to investigate trends between the two 
parameters. The analysis investigates two key areas: 1. Correlation between 
distribution margins across therapy areas and regions and 2: The relationship 
between pharmaceutical margins and GDP per capita across countries. RESULTS: 
In Asia-Pacific, we find that the distribution margins are higher for diabetic 
drugs (32%) than multiple sclerosis (23%) and oncology (16%). In Europe, a similar 
pattern follows: distribution margins in diabetes (28%), multiple sclerosis (12%) 
and oncology (12%). The margins in Middle-East-Africa and US however, remain 
constant across all three therapy areas. We found no correlation between the 
drug distribution margins and GDP aside from the Middle-East-African region, 
which showed a higher pharmaceutical margin in high GDP countries. 
CONCLUSIONS: Our analysis shows that pharmaceutical margins vary the most 
depending on region and therapy area with little correlation to the GDP per 
capita. Pharmaceutical distribution margins are higher in Asia-Pacific than in 
Middle-East-Africa, Europe and US.  
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OBJECTIVES: Use of a Common Data Model (CDM) to standardize data format 
and assumptions facilitates consistent and efficient application of research 
methods across disparate data sources, producing meaningfully comparable 
results. This study compared treatment patterns for patients diagnosed with 
depression in 2008-09 across multiple observational databases, after all source 
data was transformed into a CDM format. METHODS: Newly diagnosed 
depression patients were identified from 5 Administrative Claims and Electronic 
Health Record (EHR) databases, comprising ~300 million patients previously 
transformed into a CDM format. Patterns of initial treatment for anti-depressant 
drug classes (e.g. SSRI, SNRI, TCA, MAOI, Other) were analyzed using a common 
CDM analysis module. The Proportion of Days Covered (PDC) as well as patterns 
of continuation, discontinuation, augmentation, and switching was calculated 
for 365 days immediately following initial treatment. RESULTS: SSRIs were the 
most common first line treatment (72-75% across databases), followed by Other 
antidepressants (12-17%). The patterns of continuation varied by type of 
database: Government Claims (5%), Commercial Claims (14-15%), EHR (32%). 
Discontinuation was consistent across all Claims (65-69%) with EHR lower (46%). 
Switching rate (12-14%) and specific patterns of switching were consistent across 
all database types. Augmentation rate was consistent across all databases (7-8%); 
with the exception Government Claims (13%). The pattern of augmentation was 
variable depending on type of database. PDC was consistent across Claims (25-
28%) but varied from EHR (57%). On average across databases, TCAs had lowest 
PDC (25-28% Claims, 57% EHR) while SNRI’s had the highest (29-44% Claims, 53% 
EHR). Analysis was completed on all databases in less than two days. 
CONCLUSIONS: Common Data Models provide an efficient way of enabling 
meaningful comparisons across disparate data sources. Differences in results are 
likely due to differences in underlying populations, data capture process, and/or 
functional ability and/or incentive to record complete information in source 
data.  
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OBJECTIVES: To provide a source document in the creation of a dataset for a 
hospital and health insurer merger. METHODS: A review of the literature was 
performed to determine best practices in the development of a dataset to link 
hospital data with health insurance data. Peer reviewed articles and reports were 
retrieved from the published literature from 2002 to 2012. RESULTS: Results 
revealed a total of 30 articles and reports. A summary of this information is 
provided as a step-by-step guide on how to setup a dataset. The purpose of data 
collection should be discussed in detail. The data must be de-identified due to 
HIPAA regulations. Patient data, such as date of birth, hospital admission, 
discharge date, sex, and ICD-9 code can be combined to form an identifier that is 
nearly 100% unique and found in both hospital and payer databases. This is 
stored as a separate dataset. Additionally, a dataset from the payer should be 
extracted and stored. The resulting datasets can then be sent to a Data 
Coordinating Center, where data is evaluated for quality assurance and 
combined into one master dataset. Prior to combining datasets it is helpful to 
identify potential research outcomes of interest to ensure that the variables are 
accurately represented by the data. CONCLUSIONS: Currently, there are few 
databases that allow researchers to follow a patient from hospital admission to 
post discharge. Researchers who obtain data offering a cross sectional view of a 
patient’s health status must find creative ways to link patients over time either 
making many assumptions or using various simulation methods. A hospital and 
health insurer merger offers a unique opportunity to develop a dataset to track 
patient outcomes.  
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